Curcumin / turmeric extract

Curcumin inhibits NF-κB signalling and its downstream inflammatory mediators (COX-2, IL-1β, TNF-α), and reduces chondrocyte catabolic responses in vitro. The practical problem is that unformulated curcumin is poorly absorbed and rapidly conjugated — which is why trials use enhanced formulations (piperine co-administration, phytosome complexes, polysorbate dispersions, or whole turmeric extracts), and why comparing doses across trials is nearly meaningless.

The head-to-heads with NSAIDs

The largest trial, Kuptniratsaikul 2014 (n=367, Thai government-funded), found turmeric extract 1500 mg/day non-inferior to ibuprofen 1200 mg/day on WOMAC at 4 weeks, with fewer GI adverse events. Shep 2019 (n=139, 28 days) found curcumin 1500 mg/day matched diclofenac on pain with far fewer adverse events (13% vs 38%). Impressive-sounding — but the first has no placebo arm and only 4 weeks of follow-up, and the second is open-label. Matching an NSAID without a placebo anchor could mean both worked or both rode regression to the mean.

The placebo-controlled reality check

The most rigorous evidence is Wang 2020 (n=70, publicly funded, Annals of Internal Medicine): Curcuma longa extract modestly reduced pain versus placebo — VAS −9.1 mm on a 100 mm scale, with a confidence interval reaching nearly to zero — and had no effect on MRI effusion-synovitis volume or cartilage composition at 12 weeks. That is the field's only structural test, and it was null.

Henrotin 2019 (n=150, manufacturer co-funded) found bio-optimized curcumin improved patient global assessment and sped pain reduction versus placebo, while the cartilage-degradation biomarker Coll2-1 trended down without clean separation. The Daily 2016 meta-analysis (8 RCTs, ~600 patients) pooled a benefit for ~1000 mg/day over placebo and parity with NSAIDs — and its authors judged the base too small and short for firm conclusions.

Dose & practical notes

Trialed regimens: turmeric extract 1500 mg/day, curcumin 500 mg three times daily, bio-optimized formulations at much lower curcumin mass, and ~1000 mg/day as the meta-analytic reference. Benefits appeared within 4 weeks in most trials. Match the specific formulation and dose of a trial rather than assuming equivalence — "turmeric powder" is about 3% curcumin and is not what was tested.

Safety — including the part the field ignored

GI tolerability consistently beats NSAIDs. But turmeric supplements are a documented cause of rare, idiosyncratic herb-induced liver injury — with more reports tied to high-bioavailability, piperine-containing products — a real if uncommon harm signal. Other cautions: an antiplatelet effect (care with anticoagulants and before surgery), gallbladder contraction (gallstones), possible CYP3A4/tacrolimus interaction, and avoidance of supplemental doses in pregnancy.

What I take from it

For short-term symptom relief with less GI risk than an NSAID, curcumin has a genuinely reasonable case. For cartilage, the honest summary is one sentence: the only trial that looked at joint structure found nothing at 12 weeks, and nothing longer exists.